Emerging drugs for the treatment of benign prostatic obstruction

Bibliography

• Abrams P, Cardozo L, Fall M, The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society. Neurourol Urodyn 2002;21:167-78
   PubMed Web of Science ®Google Scholar
• Irwin DE, Milsom I, Hunskaar S, Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306-14
   PubMed Web of Science ®Google Scholar
• Abrams P, Chapple C, Khoury S, Evaluation and treatment of lower urinary tract symptoms in older men. J Urol 2009;181:1779-87
   PubMed Web of Science ®Google Scholar
• Abrams P. Benign prostatic hyperplasia: the term BPH is misused. BMJ 2008;336:405
   PubMed Web of Science ®Google Scholar
• Abrams P. New words for old: lower urinary tract symptoms for ‘prostatism’. BMJ 1994;308:929-30
   PubMed Web of Science ®Google Scholar
• Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474-9
   PubMed Web of Science ®Google Scholar
• McConnell JD, Roehrborn CG, Bautista OM, The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-98
   PubMed Web of Science ®Google Scholar
• Emberton M, Cornel EB, Bassi PF, Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management. Int J Clin Pract 2008;62:1076-86
   PubMed Web of Science ®Google Scholar
• Furuya S, Kumamoto Y, Yokoyama E, Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J Urol 1982;128:836-9
   PubMed Web of Science ®Google Scholar
• Lepor H, Tang R, Meretyk S, Shapiro E. Alpha 1 adrenoceptor subtypes in the human prostate. J Urol 1993;149:640-2
   PubMed Web of Science ®Google Scholar
• Djavan B, Chapple C, Milani S, Marberger M. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2004;64:1081-8
   PubMed Web of Science ®Google Scholar
• Milani S, Djavan B. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on alpha-adrenoceptor antagonists. BJU Int 2005;95(Suppl 4):29-36
   PubMed Web of Science ®Google Scholar
• Roehrborn CG. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. BJU Int 2006;97:734-41
   PubMed Web of Science ®Google Scholar
• Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999;36:1-13
   PubMed Web of Science ®Google Scholar
• Garimella PS, Fink HA, Macdonald R, Wilt TJ. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia. Cochrane Database Syst Rev 2009:CD007360
   Google Scholar
• Kawabe K, Yoshida M, Homma Y. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 2006;98:1019-24
   PubMed Web of Science ®Google Scholar
• Marks LS, Gittelman MC, Hill LA, Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension study. Urology 2009;74(6):1318-22
   Google Scholar
• Marks LS, Gittelman MC, Hill LA, Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol 2009;181:2634-40
   PubMed Web of Science ®Google Scholar
• Yamanishi T, Mizuno T, Tatsumiya K, Urodynamic effects of silodosin, a new alpha(1A)-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia. Neurourol Urodyn 2009 [Epub ahead of print]
   Google Scholar
• Matsukawa Y, Gotoh M, Komatsu T, Efficacy of silodosin for relieving benign prostatic obstruction: prospective pressure flow study. J Urol 2009;182:2831-5
   PubMed Web of Science ®Google Scholar
• Horvath K, Walter G, Varga A, Romics I. A novel approach to the treatment of benign prostatic hyperplasia. BJU Int 2006;97:1252-5
   PubMed Web of Science ®Google Scholar
• Shapiro E. Embryologic development of the prostate. Insights into the etiology and treatment of benign prostatic hyperplasia. Urol Clin North Am 1990;17:487-93
   PubMed Web of Science ®Google Scholar
• Silver RI, Wiley EL, Thigpen AE, Cell type specific expression of steroid 5 alpha-reductase 2. J Urol 1994;152:438-42
   PubMed Web of Science ®Google Scholar
• Schroder FH. Medical treatment of benign prostatic hyperplasia: the effect of surgical or medical castration. Prog Clin Biol Res 1994;386:191-6
   PubMedGoogle Scholar
• Gormley GJ, Stoner E, Bruskewitz RC, The effect of finasteride in men with benign prostatic hyperplasia. The finasteride study group. N Engl J Med 1992;327:1185-91
   PubMed Web of Science ®Google Scholar
• Geller J. Five-year follow-up of patients with benign prostatic hyperplasia treated with finasteride. Eur Urol 1995;27:267-73
   PubMed Web of Science ®Google Scholar
• Lepor H, Williford WO, Barry MJ, The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans affairs cooperative studies benign prostatic hyperplasia study group. N Engl J Med 1996;335:533-9
   PubMed Web of Science ®Google Scholar
• Marberger MJ. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS study group. Urology 1998;51:677-86
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Roehrborn CG, McConnell JD, Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial. J Urol 2008;180:1030-2
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Boyle P, Nickel JC, Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60:434-41
   PubMed Web of Science ®Google Scholar
• O'Leary MP, Roehrborn C, Andriole G, Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor. BJU Int 2003;92:262-6
   PubMed Web of Science ®Google Scholar
• Andriole GL, Kirby R. Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 2003;44:82-8
   PubMed Web of Science ®Google Scholar
• Debruyne F, Barkin J, van EP, Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004;46:488-94
   PubMed Web of Science ®Google Scholar
• O'Leary MP, Roehrborn CG, Black L. Dutasteride significantly improves quality of life measures in patients with enlarged prostate. Prostate Cancer Prostatic Dis 2008;11:129-33
   PubMed Web of Science ®Google Scholar
• McConnell JD, Bruskewitz R, Walsh P, The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride long-term efficacy and safety study group. N Engl J Med 1998;338:557-63
   PubMed Web of Science ®Google Scholar
• Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996;48:398-405
   PubMed Web of Science ®Google Scholar
• Klotz L, Saad F. PCPT, MTOPS and the use of 5ARIs: a Canadian consensus regarding implications for clinical practice. Can Urol Assoc J 2007;1:17-21
   PubMedGoogle Scholar
• Kirby RS, Roehrborn C, Boyle P, Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the prospective European doxazosin and combination therapy (PREDICT) trial. Urology 2003;61:119-26
   PubMed Web of Science ®Google Scholar
• Siami P, Roehrborn CG, Barkin J, Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design. Contemp Clin Trials 2007;28:770-9
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Siami P, Barkin J, The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urology 2008;179:616-21
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Siami P, Barkin J, The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study. Eur Urol 2009;55:461-71
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Siami P, Barkin J, The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010;57(1):123-31
   Google Scholar
• Baldwin KC, Ginsberg PC, Harkaway RC. Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin for bladder outlet obstruction. Urol Int 2001;66:84-8
   PubMed Web of Science ®Google Scholar
• Barkin J, Guimaraes M, Jacobi G, Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol 2003;44:461-6
   PubMed Web of Science ®Google Scholar
• Glynn RJ, Campion EW, Bouchard GR, Silbert JE. The development of benign prostatic hyperplasia among volunteers in the normative aging study. Am J Epidemiol 1985;121:78-90
   PubMed Web of Science ®Google Scholar
• Cunha GR, Battle E, Young P, Role of epithelial-mesenchymal interactions in the differentiation and spatial organization of visceral smooth muscle. Epithelial Cell Biol 1992;1:76-83
   PubMedGoogle Scholar
• Halmos G, Arencibia JM, Schally AV, High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. J Urol 2000;163:623-9
   PubMed Web of Science ®Google Scholar
• Bono AV, Salvadore M, Celato N. Gonadotropin-releasing hormone receptors in prostate tissue. Anal Quant Cytol Histol 2002;24:221-7
   PubMed Web of Science ®Google Scholar
• Comaru-Schally M. GnRH antagonists and benign prostatic hyperplasia. Ann Urol (Paris) 2005;39(Suppl 3):S73-S77
   PubMedGoogle Scholar
• Gonzalez-Barcena D, Vadillo-Buenfil M, Gomez-Orta F, Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer. Prostate 1994;24:84-92
   PubMed Web of Science ®Google Scholar
• Comaru-Schally AM, Brannan W, Schally AV, Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia. J Clin Endocrinol Metab 1998;83:3826-31
   PubMed Web of Science ®Google Scholar
• Lepor H, Dixon C, Crawford ED, A randomized double blind placebo controlled Phase II study of the safety and efficacy of Cetrorelix in men with BPH. AUA 1997. J Urol1997;157(4 suppl):136
   Google Scholar
• Debruyne F, Gres AA, Arustamov DL. Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia. Eur Urol 2008;54:170-7
   PubMed Web of Science ®Google Scholar
• Debruyne F. The efficacy and safety of ozarelix, a novel GnRH antagonist, in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) [abstract 1552]. AUA 2007. J Urol 2007;177(4 suppl):512
   Google Scholar
• Giuliano F, Behr-Roussel D, Oger S, Ozarelix, an LHRH Antagonist, exerts a direct relaxing effect on human prostate in vitro [abstract 1919]. AUA 2009. J Urol 2009;181(4 Suppl):693
   Google Scholar
• Maclean C, Larsen F, Drewe J, Efficacy and safety of teverelix LA, a new GnRH antagonist in patients with benign prostatic hyperplasia (BPH). Results from a phase II randomized, double-blind, placebo-controlled, multicentre, multinational study investigating two single injections of 60 mg at 48 hours interval administered s.c. to treatment naïve patients suffering from BPH. Eur Urol Suppl 2007;6:109
   Web of Science ®Google Scholar
• Maclean CM, Skillern L, Larsen F, Efficacy and safety of teverelix LA, a new GnRH antagonist in patients with benign prostatic hyperplasia (BPH). Results from a phase II randomised, double-blind, placebo-controlled, multicentre, multinational study investigating two single injections of 30 mg or 60 mg (separated by at least 12 weeks) administered sc to treatment naive patients suffering from BPH. Eur Urol 2008;7(Suppl):170
   Web of Science ®Google Scholar
• Bertolotto M, Trincia E, Zappetti R, Effect of Tadalafil on prostate haemodynamics: preliminary evaluation with contrast-enhanced US. Radiol Med 2009;114:1106-14
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Kaminetsky JC, Auerbach SM, Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment. BJU Int 2010;105(4):502-7
   Google Scholar
• Broderick GA, Brock GB, Roehrborn CG, Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction. Urology 2010 [Epub ahead of print]
   Google Scholar
• Dmochowski R, Roehrborn C, Klise S, Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. J Urol 2010;183:1092-7
   PubMed Web of Science ®Google Scholar
• Oger S, Behr-Roussel D, Gorny D, Combination of alfuzosin and tadalafil exerts an additive relaxant effect on human detrusor and prostatic tissues in vitro. Eur Urol 2009 [Epub ahead of print]
   Google Scholar
• Oger S, Behr-Roussel D, Gorny D, Combination of doxazosin and sildenafil exerts an additive relaxing effect compared with each compound alone on human cavernosal and prostatic tissue. J Sex Med 2009;6:836-47
   PubMed Web of Science ®Google Scholar
• Bechara A, Romano S, Casabe A, Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med 2008;5:2170-8
   PubMed Web of Science ®Google Scholar
• Tuncel A, Nalcacioglu V, Ener K, Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World J Urol 2010;28(1):17-22
   Google Scholar
• Stief C, Porst H, Evers T, Ulbrich E. Vardenafil in the treatment of symptomatic benign prostatic hyperplasia [abstract 1565]. AUA 2007. J Urol 2007;177(4 suppl):517
   Google Scholar
• Johnson P, Haughie S, Cleton A, Enhanced quantitative drug development (EQDD) of a selective PDE5 inhibitor for the treatment of benign prostatic hyperplasia (BPH). Annual Meeting of the Population Approach Group in Europe 2009 [abstract 1670]. PAGE 2009; ISSN 1871-6032; www.page-meeting.org/?abstract=1670
   Google Scholar
• Crescioli C, Ferruzzi P, Caporali A, Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia. Eur J Endocrinol 2004;150:591-603
   PubMed Web of Science ®Google Scholar
• Penna G, Fibbi B, Amuchastegui S, Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol 2009;182:4056-64
   PubMed Web of Science ®Google Scholar
• Penna G, Fibbi B, Amuchastegui S, The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways. Prostate 2009;69:480-93
   PubMed Web of Science ®Google Scholar
• Fibbi B, Penna G, Morelli A, Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl 2009 [Epub ahead of print]
   Google Scholar
• Colli E, Rigatti P, Montorsi F, BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. Eur Urol 2006;49:82-6
   PubMed Web of Science ®Google Scholar
• Montorsi F, Colli E. Elocalcitol in the treatment of BPH: a multicenter, randomized, placebo-controlled phase IIb clinical trial [abstract 2035]. AUA 2008. J Urol 2008;179(4 Suppl):700-1
   Google Scholar
• Noguchi K, Takeda M, Hosaka M, Kubota Y. Clinical effects of allylestrenol on patients with benign prostatic hyperplasia (BPH) evaluated with criteria for treatment efficacy in BPH. Hinyokika Kiyo 2002;48:269-73
   PubMedGoogle Scholar
• Noguchi K, Suzuki K, Teranishi J, Recovery of serum prostate specific antigen value after interruption of antiandrogen therapy with allylestrenol for benign prostatic hyperplasia. Hinyokika Kiyo 2006;52:527-30
   PubMedGoogle Scholar
• Ueki O, Kawaguchi K, Katsumi T, Clinical efficacy and reduction effect on prostatic volume of chlormadinone acetate combined with tamsulosin hydrochloride in benign prostatic hyperplasia patients insufficiently treated with tamsulosin hydrochloride only. Hinyokika Kiyo 1998;44:565-73
   PubMedGoogle Scholar
• Fujimoto K, Hirao Y, Masumori N, Prostate-specific antigen changes as a result of chlormadinone acetate administration to patients with benign prostatic hyperplasia: a retrospective multi-institutional study. Int J Urol 2006;13:543-9
   PubMed Web of Science ®Google Scholar
• Okada H, Kawaida N, Ogawa T, Tamsulosin and chlormadinone for the treatment of benign prostatic hyperplasia. The kobe university YM617 study group. Scand J Urol Nephrol 1996;30:379-85
   PubMed Web of Science ®Google Scholar
• Denmeade S, Pommerville PJ, Steinhoff G, PRX302 is a transperineally administered, PSA-activated protoxin that produces symptomatic relief in men with moderate to severe BPH (MP-06.13). Urology 2009;74:S72-S73
   Google Scholar
• Ilie CP, Chancellor MB, Chuang YC, Dan M. Intraprostatic botulinum toxin injection in patients with benign prostatic enlargement. J Med Life 2009;2:338-42
   PubMedGoogle Scholar
• Ilie CP, Chancellor MB. Perspective of Botox for treatment of male lower urinary tract symptoms. Curr Opin Urol 2009;19:20-5
   PubMed Web of Science ®Google Scholar
• Maria G, Brisinda G, Civello IM, Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 2003;62:259-64
   PubMed Web of Science ®Google Scholar
• Kuo HC, Liu HT. Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy. Scand J Urol Nephrol 2009;43:206-11
   PubMed Web of Science ®Google Scholar
• Preuss HG, Marcusen C, Regan J, Randomized trial of a combination of natural products (cernitin, saw palmetto, B-sitosterol, vitamin E) on symptoms of benign prostatic hyperplasia (BPH). Int Urol Nephrol 2001;33:217-25
   PubMedGoogle Scholar
• Tacklind J, Macdonald R, Rutks I, Wilt TJ. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2009:CD001423
   Google Scholar
• Wilt T, Ishani A, Mac DR, Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev 2002:CD001044
   Google Scholar
• Lee J, Andriole G, Avins A, Redesigning a large-scale clinical trial in response to negative external trial results: the CAMUS study of phytotherapy for benign prostatic hyperplasia. Clin Trials 2009;6:628-36
   PubMed Web of Science ®Google Scholar
• Wilt T, Ishani A, Macdonald R, Beta-sitosterols for benign prostatic hyperplasia. Cochrane Database Syst Rev 2000:CD001043
   Google Scholar
• Kristal AR, Arnold KB, Schenk JM, Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol 2008;167:925-34
   PubMed Web of Science ®Google Scholar
• St Sauver JL, Jacobson DJ, McGree ME, Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia. Am J Epidemiol 2006;164:760-8
   PubMed Web of Science ®Google Scholar
• Falahatkar S, Mokhtari G, Pourreza F, Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study. Urology 2008;72:813-6
   PubMed Web of Science ®Google Scholar
• Araki T, Yokoyama T, Araki M, Furuya S. A clinical investigation of the mechanism of loxoprofen, a non-steroidal anti-inflammatory drug, for patients with nocturia. Acta Med Okayama 2008;62:373-8
   PubMed Web of Science ®Google Scholar
• Wong SY, Lau WW, Leung PC, The association between isoflavone and lower urinary tract symptoms in elderly men. Br J Nutr 2007;98:1237-42
   PubMed Web of Science ®Google Scholar
• Wennemuth G, Aumuller G. Angiotensin II-mediated calcium signals and mitogenesis in human prostate stromal cell line hPCPs. Br J Pharmacol 2005;144:3-10
   PubMed Web of Science ®Google Scholar
• Schroder A, Tajimi M, Matsumoto H, Protective effect of an oral endothelin converting enzyme inhibitor on rat detrusor function after outlet obstruction. J Urol 2004;172:1171-4
   PubMed Web of Science ®Google Scholar
• Rees RW, Foxwell NA, Ralph DJ, Y-27632, a Rho-kinase inhibitor, inhibits proliferation and adrenergic contraction of prostatic smooth muscle cells. J Urol 2003;170:2517-22
   PubMed Web of Science ®Google Scholar